ETFs Lineage Cell Therapeutics, Inc.

LCTX

US53566P1093

Biotechnology & Medical Research

Market Closed - NYSE 16:00:00 2026-10-19 EDT			5-day change	1st Jan Change
0.9528 ^USD	-2.61%		-0.14%	-42.95%

09-30	EARNINGS: Generation Essentials interim profit jumps to USD28 million	AN
08-07	Lineage Cell Therapeutics, Inc., Q2 2026 Earnings Call, Aug 06, 2026

ETFs positioned on Lineage Cell Therapeutics, Inc.

Name	YTD change	Weight	AuM
ISHARES BIOTECHNOLOGY ETF - USD	+20.91%	0.04%	9,953 M€
VANGUARD EXTENDED MARKET ETF - USD	+8.63%	0%	32,130 M€
STATE STREET SPDR RUSSELL 2000 U.S. SMALL CAP UCITS ETF - USD	+10.48%	0%	5,739 M€
LEUTHOLD CORE ETF - USD	+5.55%	0%	68 M€
VANGUARD MORNINGSTAR TOTAL STOCK MARKET ETF - USD	+12.01%	0%	692,025 M€
VANGUARD MORNINGSTAR U.S. TOTAL MARKET INDEX ETF - CAD	+15.24%	0%	14,144 M€
VANGUARD GROWTH ETF PORTFOLIO - CAD	+10.46%	0%	7,793 M€
UPAR ULTRA RISK PARITY ETF - USD	-2.01%	0%	59 M€
VANGUARD ALL-EQUITY ETF PORTFOLIO - CAD	+15.21%	0%	12,086 M€
ELM MARKET NAVIGATOR ETF - USD	+7.10%	0%	594 M€
VANGUARD CONSERVATIVE ETF PORTFOLIO - CAD	+3.28%	0%	688 M€
VANGUARD BALANCED ETF PORTFOLIO - CAD	+6.79%	0%	4,204 M€
DEFINED DURATION 20 ETF - USD	+10.38%	0%	19 M€
RPAR RISK PARITY ETF - USD	+0.04%	0%	580 M€
CAMBRIA TAX AWARE ETF - USD	+6.17%	0%	26 M€
VANGUARD CONSERVATIVE INCOME ETF PORTFOLIO - CAD	-0.22%	0%	184 M€
VANGUARD RETIREMENT INCOME ETF PORTFOLIO - CAD	+0.85%	0%	267 M€
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD	+4.79%	0%	37 M€
ISHARES LIFEPATH TARGET DATE 2030 ETF - USD	+5.54%	0%	80 M€
CLEARSHARES OCIO ETF - DISTRIBUTING - USD	+7.82%	0%	176 M€
AB US EQUITY ETF - USD	+9.90%	0%	727 M€
CAMBRIA US EW ETF - USD	+9.82%	0%	194 M€
ALPHA ARCHITECT US EQUITY 2 ETF - USD	+11.36%	0%	513 M€
DEFINED DURATION 5 ETF - USD	+0.06%	0%	18 M€
CAMBRIA GLOBAL EW ETF - USD	+7.54%	0%	146 M€
CAMBRIA ENDOWMENT STYLE ETF - USD	+11.44%	0%	156 M€
WARREN STREET GLOBAL EQUITY ETF - USD	+12.38%	-.--%	62 M€

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).

Employees

Sector

Biotechnology & Medical Research

More about the company